Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Other Accumulated Expenses (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Other Accumulated Expenses for 6 consecutive years, with $196000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 157.89% to $196000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $196000.0, a 157.89% increase, with the full-year FY2025 number at $196000.0, up 157.89% from a year prior.
  • Other Accumulated Expenses was $196000.0 for Q4 2025 at TScan Therapeutics, up from $189000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.3 million in Q3 2022 to a low of $76000.0 in Q4 2024.
  • A 5-year average of $438789.5 and a median of $425000.0 in 2023 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 666.67% in 2021, then tumbled 82.12% in 2024.
  • TScan Therapeutics' Other Accumulated Expenses stood at $1.0 million in 2021, then tumbled by 57.41% to $431000.0 in 2022, then decreased by 1.39% to $425000.0 in 2023, then crashed by 82.12% to $76000.0 in 2024, then skyrocketed by 157.89% to $196000.0 in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Other Accumulated Expenses are $196000.0 (Q4 2025), $189000.0 (Q3 2025), and $190000.0 (Q2 2025).